Wealth Daily submits:By Adam SharpDelcath Systems (NASDAQ:DCTH) surged 30% in after-hours trading Wednesday. The company announced positive clinical data for their proprietary liver cancer treatment system, The Delcath Percutaneous Hepatic Perfusion (PHP) device.Complete Story »
Douglas Estadt submits: Delcath Systems, Inc. (DCTH) is a medical technology company specializing in cancer treatment, with its initial focus on the treatment of primary and metastatic liver cancers. DCTH recently presented at the American Society of Clinical Oncology ((ASCO)) Annual Meeting and results were very positive.
David Greene submits:From a low of $4.05 in February to the current price of $14.30 (May 19), Delcath Systems, Inc. (Nasdaq: DCTH) has had an enviable run up as the market anticipated positive results in their clinical trials and then celebrated those results.
Douglas Estadt submits: Delcath Systems (DCTH) is a biotech stock that does pose some risk, but with Phase III results just around the corner, we couldn’t help but take a look and ended up buying. They develop and manufacture devices to give high doses of chemotherapy and other cancer therapies directly to diseased organs or areas of the body.
By Mike Havrilla:Delcath Systems (DCTH) is a cancer biotech focused on the development and commercialization of a medical device/drug combo product designed for the local delivery of high-dose chemo drugs to the liver with a goal of improving treatment outcomes while minimizing side effects typically associated with systemic/whole body exposure.FDA CATALYST SUMMARY:
By Steven Bulwa: Delcath (DCTH) is a specialty pharmaceutical and medical device company focused on oncology, initially cancers in the liver that recently made the first commercial sale of its CHEMOSAT system in Europe. CHEMOSAT, Delcath's chemosaturation system, allows the administration of concentrated regional chemotherapy by isolating the circulatory system of the targeted organ.
By Justin Kuepper:There are many companies operating in the cancer treatment space with near-term catalysts, including Celsion Corporation's (CLSN) ThermoDox, Threshold Pharmaceuticals' (THLD) TH-302 and even Dendreon Corporation (DNDN), whose Provenge has already been approved.
By Thomas Meyer:Celsion Corporation (CLSN) has announced they will be releasing their Phase III trial results for liver cancer by the end of January 2013. Let's look at the option skew to determine during which expiration cycle the market anticipates the result.